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ABSTRACT
Collagen–vascular diseases (CVD) involve many
organs. Among organ involvements, pulmonary dis-
orders may determine the prognosis of CVD. Because
the vasculature and blood perfusion are commonly
altered in CVD, we have attempted to analyze pulmo-
nary disorders from the viewpoint of pulmonary vessels
and perfusion. Based on routine pulmonary function
tests, many patients were observed to have a decreased
diffusion capacity (DLco) isolated from or comparative
to lung volumes. In these patients, matched ventilation/
perfusion scintigraphy revealed a decrease in pulmo-
nary peripheral perfusion. These findings may be an
early sign of pulmonary hypertension, which develops
as a result of several pathophysiological causes in
CVD. When a remedy for each pathogenesis of
pulmonary hypertension was applied, more than half
the patients recovered, at least initially; therefore, early
diagnosis, including the methods described above,
and treatment are important. With regard to pneumon-
itis in amyopathic dermatomyositis, which has been
considered to develop acutely, we observed its pro-
gression to be subacute in its early stage. Along with
this disease, pneumomediastinum characteristically
develops simultaneously with vasculopathy. Disease-
modifying antirheumatic drugs, which must be
perfused into the blood stream, sometimes induce
lymphocyte alveolitis or pneumonitis in good respond-
ers, with a decrease in the peripheral blood lympho-
cyte count and immunoglobulin levels. Examinations,
differential diagnoses, therapies and studies from the
viewpoint of the blood circulation and vessels may be
important and useful for clinical studies and for
the  further investigation of pulmonary involvement
in CVD.
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INTRODUCTION
Collagen–vascular diseases (CVD) are chronic inflam-
matory illnesses associated with immune system dis-
orders, involving many organs. Of these organs, the
lung is important and its involvement may diminish
the quality of life or the activities of daily living, as well
as indicating a poor prognosis (Table 1). Approximately
half the 34 CVD patients who were admitted to our
department in the past 5 years died of pulmonary
diseases, including interstitial pneumonitis in three cases
and pulmonary hypertension in two.
All parts of the lung may be involved, along the same
line that all organs are potentially injured in CVD. How-
ever, until recently, pulmonary diseases were mostly
studied in terms of their alveolar aspect, with analysis of
bronchoalveolar lavage fluid as a representative of that
point of view. In contrast, we have attempted to investi-
gate lung involvement in CVD from the viewpoint of
pulmonary vessels, because vascular changes are very
common manifestations of CVD.
DECREASED DIFFUSION CAPACITY ISOLATED 
FROM OR COMPARATIVE TO LUNG VOLUMES
We treated a girl with systemic lupus erythematosus (SLE)
complicated with severe Raynaud’s phenomenon, whose
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routine pulmonary function tests (PFT) revealed a
decreased diffusion capacity (DLco), as low as one-half
of the predicted value, despite normal lung volumes
(Fig. 1). Repeated PFT revealed the same results in
subsequent years, but there was no abnormality on chest
X-ray and no rales could be heard on auscultation. Since
then, a substantial number of patients, including those
with Raynaud’s phenomenon, have been found to show
a decreased DLco despite almost normal lung volumes.
If ventilation from the mouth to the alveoli is normal,
alveolar wall thickening unlikely and peripheral blood
hemoglobin levels normal, then the isolated decrease in
DLco is probably due to decreased perfusion in the
alveolar capillary bed around the alveoli.
We used matched ventilation/perfusion (V
•
/Q
•
) scin-
tigraphy to reveal a decrease in perfusion relative to
ventilation in a matched area (Fig. 2). When a pixel or
a  range of interest (ROI) in the scintigram showed
decreased peripheral perfusion compared with ventila-
tion, the (V
•
/Q
•
)  ratio  of  a  pixel  or  ROI  increased (Fig. 3).1
The (V
•
/Q
•
)  scintigram  of  the  patient  described above
revealed a dense area in the pulmonary periphery with an
increased (V
•
/Q
•
)  ratio,  which  indicated  decreased  pul-
monary peripheral perfusion. Using this methodology,
many patients with an isolated decrease in DLco have
been confirmed to have an area with a high (V
•
/Q
•
)  ratio,
mostly in the periphery. Most of these patients were also
found to have vascular impairments in the extremities.2
THE V/Q RATIO IN PULMONARY HYPERTENSION
A probable outcome of decreased pulmonary peripheral
perfusion may be pulmonary hypertension. Our cases
of CVD with pulmonary hypertension showed both an
isolated decrease in DLco, or decreased DLco com-
parative to lung volumes (Fig. 4), as well as a dense
peripheral shadow on the (V
•
/Q
•
) scintigram (Fig. 5).
In CVD, several underlying disorders may be con-
sidered to cause disturbances in peripheral perfusion,
including vasoconstriction, thickening of the endothelial
intima, thrombi, vasculitides, hypergammaglobulinemia,
veno-occlusion and parenchymal diseases. Among
these, vasoconstriction, endothelial thickening and lung
fibrosis are the three major underlying disorders,
although more than one pathogenesis frequently over-
lap. Our patients with pulmonary hypertension were
treated on a case-by-case basis by first determining how
peripheral perfusion was disturbed in each patient. As a
result, two-thirds of 24 patients improved at least initially
and more than one-half survived for more than 3 years.
VASCULOPATHY IN AMYOPATHIC 
DERMATOMYOSITIS
Interstitial pneumonitis complicated with amyopathic
dermatomyositis (amyo-DM) is known to be acutely pro-
gressive and occasionally severe with a poor prognosis.
Recently, we have treated five patients with amyo-DM
associated with pneumonitis. All had typical skin lesions
and, in addition, persistent ulcerations in the skin or
mucous membrane lesions were noted, suggesting an
underlying vasculopathy. During the course of their ther-
apy, pneumomediastinum developed in all five patients.
 
Table 1 Causes of 34 deaths during the period 1998–2002
in the Department of Allergy and Immunological Diseases,
Tokyo Metropolitan Komagome Hospital (Tokyo, Japan)
No. deaths
Pulmonary diseases (total) 16
Interstitial pneumonitis 3
Pulmonary hypertension 2
Respiratory infection 8
Other 3
Other 18
Fig. 1 Pulmonary function in a female patient with systemic
lupus erythematosus. (), vital capacity; (), total lung capacity;
(), functional residual capacity; (), forced expiratory volume
in 1 s; (), diffusion capacity (DLco); (λ), DLco/alveolar volume
(VA). Both DLco and DLco/VA were inconsistently low with
almost normal lung volumes. The patient had severe Raynaud’s
phenomenon from 17 to 37 years of age.
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Fig. 2 Matched ventilation (133Xe gas)/perfusion (99mTc-macroaggregated albumin) scintigraphy. Images are obtained sequentially
in the same position and the ventilation/perfusion (V
•
/Q
•
)  ratio  for  each  pixel  is  calculated  and  drawn;  a  high  density  indicates  a
high ratio.
Fig. 3 Ventilation/perfusion (V
•
/Q
•
)  image  of  a  39-year-old
female patient with dermatomyositis with diffusion capacity of
48% and a vital capacity of 108% of predicted values.
Fig. 4 Ventilation/perfusion (V
•
/Q
•
)  image  of  a  60-year-old
female patient with systemic sclerosis and pulmonary hyper-
tension. Scant perfusion was indicated in the lower fields of both
lungs.
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Bronchoscopy performed on a 30-year-old male patient
revealed a necrotic lesion in the bronchial mucosa, which
was confirmed by biopsy (Fig. 6).3 Pneumomediastinum
in amyo-DM may be caused by bronchial mucosal ulcer-
ation that is related to the underlying vasculopathy.
Among our patients with myopathic DM, only one patient
developed pneumomediastinum, who had old tuberculo-
sis. Cutaneous vasculopathy was significantly more fre-
quent in five patients with pneumomediastinum than in
44 DM/polymyositis patients without it. Examination of
previous reports of 13 patients with polymyositis or DM
complicated by pneumomediastinum revealed that 10 of
13 patients had pneumonitis, and five had cutaneous
vasculopathy.3
When the pulmonary findings of our five patients were
analyzed retrospectively, we found that the changes had
already started a few months before, although hardly any
symptoms had been noted subjectively. We may suppose
that interstitial pneumonitis complicated by amyo-DM
does not progress acutely, but subacutely.
 
Fig. 5 Vital capacity (VC) compared with diffusion capacity
(DLco) in 24 patients with pulmonary hypertension associated
with collagen–vascular disease. Three patients with a higher
percentage of the predicted value for DLco than that for VC had
pulmonary fibrosis. Mean (±SEM) values for %VC and %DLco
were 66.1 ± 23.6 and 39.0 ± 17.6%, respectively.
Fig. 6 Necrosis of the bronchial mucosa observed in a
30-year-old male patient with amyopathic dermatomyositis
complicated by pneumomediastinum.
Fig. 7 Bucillamine-induced lung injury in a 74-year-old
female patient with rheumatoid arthritis.
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Although one of the five patients, a 25-year-old man,
had a poor prognosis, four survived and the pulmonary
findings in these four patients, including radiographic
findings, were gradually improved with steroid treatment,
alone or in combination with cyclophosphamide.
DISEASE-MODIFYING ANTIRHEUMATIC 
DRUG-INDUCED LUNG INJURY
A number of pulmonary diseases having a vascular
pathogenesis are probably drug induced. Today, disease-
modifying antirheumatic drugs (DMARD) are among
those drugs that potentially cause adverse reactions in
the lung.
Principally, reversible drug-induced lung injuries are
observable radiographically as diffuse bilateral infiltra-
tions that usually appear acutely or subacutely and dis-
appear following cessation of the drug. When we treated
rheumatoid arthritis patients with bucillamine, an occa-
sional lung injury developed exclusively after the drug
had taken effect; the radiographic findings were mottled
dense infiltrates around the bronchovascular bundles,
distributed in the upper and middle lung fields and
sparing the periphery, which contrasted with the radio-
graphic findings in usual interstitial pneumonitis or
fibrosis complicated by rheumatoid arthritis (Fig. 7).4
These radiographic findings are similar to those reported
for gold-induced lung injury. On auscultation, no rale
was audible. We found that our patients had decreased
serum immunoglobulin levels at the onset of bucillamine-
induced lung injury, that re-increased to the levels at
rheumatoid arthritis remission. Until recently, two major
types of drug-induced adverse reactions have been con-
sidered: (i) allergic hypersensitivity; and (ii) cell toxicity.
Because bucillamine could be reintroduced successfully
and because adverse events did not appear to be dose
dependent in patients treated by bucillamine, neither
hypersensitivity nor toxicity was likely.
Methotrexate-induced lung injuries that we treated in
nine rheumatoid patients were much more severe;
radiographic infiltrates were intensely diffused predomi-
nantly in the upper and middle lung fields, sparing the
lung base. Respiratory distress was severe, in that PaO2
decreased to as low as below 30 mmHg and C-reactive
protein increased up to 30 mg/dL with high fever. All
patients responded to methotrexate treatment for arthritis.
Immunoglobulin levels decreased at the onset of lung
injury, then increased to levels measured at arthritis
remission. The peripheral blood lymphocyte count, which
had remained unchanged during arthritis remission,
decreased at the onset of lung injury and returned to
normal levels after its improvement. After our study,
two new patients were diagnosed as having early stage
methotrexate-induced lung injury with slight fever and
cough. Computed tomography images revealed patchily
distributed thin infiltrates and the lymphocyte count and
immunoglobulin level decreased.5 Bronchovascular lavage
fluid from four patients revealed many CD3-positive
cells, the majority of which were also CD4 positive, as
was noted in the earlier studies. A DMARD that circulates
via the blood to the joints and lungs may remit arthritis in
a responder, but may also induce lymphocytic alveolitis.
REFERENCES
1 Suzuki K, Kamata N, Inokuma S et al. Clinical signifi-
cance of ventilation/perfusion scans in collagen disease
patients. Ann. Nucl. Med. 2000; 14: 405–13.
2 Kono H, Inokuma S. Vascular impairment both in lungs
and fingers in patients with systemic rheumatic diseases.
Chest 2003; 124: 255–61.
3 Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumo-
mediastinum in dermatomyositis: Association with cutan-
eous vasculopathy. Ann. Rheum. Dis. 2000; 59: 372–6.
4 Inokuma S, Sakata M, Yoshida A, Shiratori K,
Kiyosawa H. Bucillamine induced pulmonary injury
occurs with immunoglobulin decrease. J. Rheumatol.
1996; 23: 1282–5.
5 Inokuma S, Kono H, Nakayama H, Yamazaki J.
Immunoglobulin and lymphocyte decrease concurrent
with adverse reactions induced by methotrexate for RA.
Ann. Rheum. Dis. 2000; 59: 495–6.
 
